Watch LENZ. Know when insiders buy.
One email the day a filing lands. Free.
LENZ
LENZ Therapeutics, Inc.
4.07
−0.06 −1.45%
USD · close Sep 18
A free account adds a watchlist, alerts when insiders, Congress or short sellers move on your tickers, and a morning brief. Sign up
Work order
57
WATCH · shorts 57
Insiders, 90 days
0
no open-market filings in 90 days
Congress, 90 days
0 / 0
no disclosures naming it
Big money
0 / 15
none of the tracked funds disclose it
Calls on record
0
nobody we score has called it yet
MKT CAP $127.9MP/E —DIV YIELD —FCF YIELD -89.47%REV TTM —NET INCOME −$126MNET CASH —52W 4.07 – 49.05SEC XBRL · TTM TO Invalid Date
Financials
By quarter
| Period | Revenue | YoY | Gross margin | Operating income | Net income | YoY | EPS | Op. cash flow | Capex | Free cash flow | Filed |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Q2 2026 · Jun 30 | $5.5M | +9.7% | 94.9% | −$34.2M | −$31.9M | — | -1.02 | −$38.7M | $16K | −$38.7M | Aug 11 |
| Q1 2026 · Mar 31 | $1.9M | — | 43.4% | −$44.1M | −$41.5M | — | -1.32 | −$33.6M | $18K | −$33.6M | Aug 11 |
| Q4 2025 · Dec 31derived | — | — | — | −$38.5M | −$35.9M | — | -1.20 | −$33M | $38K | −$33.1M | Mar 24 |
| Q3 2025 · Sep 30 | — | — | — | −$18.9M | −$16.7M | — | -0.59 | −$8.6M | $439K | −$9M | Nov 5 |
| Q2 2025 · Jun 30 | $5M | — | 100.0% | −$16.9M | −$14.9M | — | -0.53 | −$11.5M | $240K | −$11.7M | Aug 11 |
| Q1 2025 · Mar 31 | $0 | — | — | −$16.9M | −$14.6M | — | -0.53 | −$16M | $110K | −$16.2M | Aug 11 |
| Q4 2024 · Dec 31derived | — | — | — | −$15.2M | −$12.7M | — | -0.41 | −$9.1M | $149K | −$9.2M | Mar 24 |
| Q3 2024 · Sep 30 | — | — | — | −$12.9M | −$10.2M | — | -0.38 | −$10.6M | $186K | −$10.8M | Nov 5 |
| Q2 2024 · Jun 30 | — | — | — | −$14.4M | −$10.3M | — | -0.40 | −$15.8M | $133K | −$15.9M | Nov 5 |
| Q1 2024 · Mar 31 | — | — | — | −$16.1M | −$16.6M | — | -3.53 | −$23.9M | $0 | −$23.9M | Nov 5 |
| Q4 2023 · Dec 31derived | — | — | — | −$25M | −$23.7M | — | -12.05 | −$21M | $0 | −$21M | Mar 19 |
| Q3 2023 · Sep 30 | — | — | — | −$19.9M | −$18.9M | — | -9.62 | −$13.1M | $0 | −$13.1M | Nov 6 |
By fiscal year
| Year | Revenue | Gross margin | Operating income | Net income | Net margin | EPS | Op. cash flow | Capex | Free cash flow | Buybacks | Dividends paid |
|---|---|---|---|---|---|---|---|---|---|---|---|
| FY2025 · to Dec 31 | $19.1M | 97.8% | −$91.1M | −$82.1M | -430.3% | -2.85 | −$69.2M | $827K | −$70M | — | — |
| FY2024 · to Dec 31 | $0 | — | −$58.6M | −$49.8M | — | -2.34 | −$59.4M | $468K | −$59.9M | — | — |
| FY2023 · to Dec 31 | — | — | −$72.4M | −$70M | — | -35.71 | −$60.4M | $30K | −$60.4M | — | — |
| FY2022 · to Dec 31 | — | — | −$105.6M | −$101.1M | — | -1.84 | −$88M | $6.6M | −$94.6M | — | — |
| FY2021 · to Dec 31 | — | — | −$60.4M | −$70.8M | — | -2.45 | −$52.9M | $5.7M | −$58.6M | — | — |
| FY2020 · to Dec 31 | — | — | −$13.5M | −$68.4M | — | -29.93 | −$8.7M | $1.5M | −$10.3M | — | — |
Every number comes from LENZ Therapeutics, Inc.'s own XBRL-tagged filings with the SEC, not a data vendor. Quarters marked derived are the fiscal year minus the three reported quarters, the same way every data provider computes Q4. Restated figures replace originals as later filings arrive.